China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
China
China / Hong Chow Leaves Roche for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General Manager for Roche…
China / A New Era of Reform Transforming Regulatory Professionals
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
In Conversation
Qing Liu – VP, Clinical & Regulatory Affairs, Arctic Vision, China
Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market. Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers in this area Qing, as a PhD trained in ophthalmology,…
APAC / Generic Penetration by Country
Generics penetration in the Asia-Pacific region by country for 2018. A full 90.3 percent of all medicines dispensed…
Related Report
Legal & Regulatory / China: Amended Drug Registration Regulation Aims to Strengthen and Streamline Regulation of New Drugs
On March 30, 2020, the State Administration for Market Regulation (SAMR) enacted the Amended Drug Registration…
China / 3rd Drug Procurement Round a Bloodbath for Multinationals
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used…
Regulation / China Cracks Down on Counterfeit and Substandard Drugs
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the…
US-China Tensions Heating Up in the Life Sciences
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war…
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
The Ideal Pharma Country Manager: China (Cornerstone International)
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in…
China / EpimAb Looks to 2022 IPO & Global Leadership in Bispecific Antibodies
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking…
5 Biotechs to Watch in China
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology…
China / Antitrust Threat to Pharma; June BioNTech Vaccine Approval; EpimAb IPO; CanSino Inhaled Vaccine Trials
The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in…
News Roundup / China Pharma June 29th 2020
The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
Report / New China Pharma Report February 2020 Out Now
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of…
China / 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine…
Pharma Faces / Felix Gutsche, Boehringer Ingelheim China
2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three…
Biotech / 5 More Biotechs to Watch in China
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making…
Company Spotlight / Zai Lab, China
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
Global / PharmaBoardroom's Top 5 Op-Eds in 2021 (So Far)
As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read…
Bio 2019 / Hong Kong Biotech IPOs Soaring in Line with China Pharma Market
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019…
China: Driving Big Pharma’s Sales Growth for the Long Term?
China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
News Roundup / China Biotech June 15th 2020
A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million…
China / Sinopharm Vaccine Approval; Online Healthcare Boom; 51% Drug Price Cuts
The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how…
CanSinoBIO / China's Leading COVID-19 Vaccine Developer Talks Timelines
Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in…
APAC / How Precision Medicine is Transforming the Oncology Landscape
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer…
China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
News Roundup / Chinese Pharma May 4th 2020
A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy,…
Company Profile / Servier China, 40 Years of Commitment
2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also…
Regulatory Reform in China / The New Drug Administration Law
On 26 August 2019, the Chinese legislature, the National People’s Congress (NPC), passed the new Drug…